Is the GSK share price set to soar after £50bn Unilever bid?

The GSK share price could see some serious price action on Monday morning, after FTSE 100 giant Unilever made a £50bn bid for GSK Consumer Healthcare.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sparks could fly on the London Stock Exchange after news of a huge takeover bid emerged this morning. According to a report on The Sunday Times website, consumer-goods Goliath Unilever (LSE: ULVR) made an unsolicited approach to pharma giant GlaxoSmithKline (LSE: GSK). The report claims that Unilever approached GSK in late 2021, offering £50bn ($68.4bn) for GSK’s Consumer Healthcare division. Thus, both the GSK share price and Unilever shares could see sharp moves when the London market opens at 8am on Monday.

Britain’s third-biggest bid initially rejected

According to the Financial Times, Unilever’s £50bn bid is the third-largest in British history. It’s topped only by Vodafone’s purchase of Germany’s Mannesmann in 1999 (during the dotcom boom). And by AB InBev’s acquisition of SABMiller in 2016. Early reports claim that Unilever’s £50bn bid was roundly rejected by GSK’s directors as significantly undervaluing its Consumer Healthcare joint venture. This follows established City tradition, which dictates that initial bids are always turned away. Typically, it can take three or more rising offers before a company’s directors and shareholders succumb to a knockout bid. Recent news reports estimated GSK Consumer Healthcare’s valuation at perhaps £40bn. But the division was valued internally at £47bn to £48bn. Hence, with Unilever offering such a small bid premium, it comes as no surprise that its first approach was declined. Nevertheless, the GSK share price may be volatile going forward.

The GSK share price has underperformed for years

The GSK share price has gone nowhere of late, having gained just 6.2% over the past five years. What’s more, the stock is far below its all-time peak. On 8 January 1999 — again during the dotcom boom — GSK stock peaked at an intra-day high of 2,333p, before easing to a record closing level of 2,288p.

This afternoon, Unilever confirmed that it approached GSK and joint-venture partner Pfizer about buying GSK Consumer Healthcare, due to be spun off this year. Pfizer owns almost a third (32%) of GSK Consumer Healthcare. However, what’s unclear is how Unilever would fund and structure this bid. In my experience, bids of such size usually consist of a mixture of cash, plus shares in the bidder. However, corporate borrowing rates are hovering near record lows and Unilever enjoys a premium credit rating. Hence, it’s possible that it could have assembled an all-cash offer.

What next?

Unilever said: “GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio.” Indeed, combining GSK’s consumer-facing brands with Unilever’s could bring significant savings and synergies. However, the Anglo-Dutch firm would have to stump up a significant premium to win over GSK’s CEO Dame Emma Walmsley and her team. Finally, whatever does happen going forward, negotiations are sure to be tricky and drawn-out. Of course, both companies are no stranger to major corporate activity. GSK is the product of multiple mergers, while Unilever fended off a gargantuan takeover bid from Warren Buffett and other backers in January 2017. For now, let’s see what happens to the GSK share price and Unilever stock on Monday morning.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline, Unilever, and Vodafone. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »